 |
市場調查報告書
商品編碼
2008054
先天性高胰島素血症治療市場：依疾病類型、藥物類型、給藥途徑、通路及地區分類Congenital Hyperinsulinism Treatment Market, By Disease Type, By Drug Type, By Route of Administration, By Distribution Channel, By Geography |
||||||
2026年先天性高胰島素血症治療市場規模估計為1.584億美元，預計2033年將達到3.216億美元。預計2026年至2033年，該市場將以8.2%的複合年成長率成長。
| 報告範圍 | 報告詳情 | ||
|---|---|---|---|
| 基準年： | 2025 | 2026年市場規模： | 1.584億美元 |
| 歷史數據時期： | 2020年至2024年 | 預測期： | 2026年至2033年 |
| 2026年至2033年預測期間的複合年成長率： | 8.20% | 2033年市場規模預測： | 3.216億美元 |
先天性高胰島素血症（CHI），又稱高胰島素血症誘發的低血糖症，是一種罕見的內分泌疾病，可導致低血糖。它主要影響新生兒、嬰幼兒和兒童，可導致永久性腦損傷，也是嚴重低血糖最常見的原因。胰島BETA細胞過度分泌胰島素會導致KATP通道基因（ABCC8、KCNJ11、HNF4A、HNF1A、HADH、UCP2）基因突變，或GLUD1、GCK和SLC16A1基因發生活化突變，進而導致先天性高胰島素血症。由於CHI具有較高的永久性腦損傷風險，因此必須快速診斷和及時治療，以預防癲癇、腦性麻痹和神經發育障礙等併發症。根據罕見疾病組織（NORD）資料庫，在大多數國家，先天性高胰島素血症（CHI）的發生率約為每25,000至50,000名新生兒中就有1例，許多患兒在出生後第一個月內會出現低血糖。易怒、嗜睡、過度飢餓和心搏過速加速是常見症狀，但也可能出現更嚴重的症狀，例如癲癇發作和昏迷。先天性高胰島素血症有多種亞型，病因也多元。例如，有些類型是暫時性的，而有些類型則是由基因缺陷引起的，並且會持續終生。早產兒可能因胰島素分泌過多而出現低血糖。這種胰島素分泌異常的原因尚不清楚，但永續數天至數月。
市場動態
預計在預測期內，西蘭製藥（Zealand Pharma A/S）、韓美製藥（Hanmi Pharm.Co., Ltd.）和禮來公司（Eli Lilly and Company）等主要企業將推動全球先天性高胰島素血症治療市場的成長，因為它們將繼續開發治療先天性高胰島素血症的新治療方法。例如，2019年5月，生技公司西蘭製藥啟動了升糖素 ）的III期臨床試驗。本試驗旨在評估升糖素治療兒童先天性高胰島素血症的療效和安全性。該試驗預計於2022年12月完成。升糖素是一種升糖素肽類似物，包含七個胺基酸替換，旨在消除纖維形成和胜肽聚集。
本次考試的主要特點。
- 本報告對全球先天性高胰島素血症治療市場進行了詳細分析，以 2021 年為基準年，給出了預測期（2022-2030 年）的市場規模和復合年成長率 (CAGR%)。
- 本報告指出了各個細分市場的潛在商機，並說明了該市場中一系列有吸引力的投資提案。
- 此外，本研究還提供了有關市場促進因素、限制因素、機會、新產品發布和核准、市場趨勢、區域展望以及主要企業採取的競爭策略的重要見解。
- 本報告根據以下參數分析了全球先天性高胰島素血症治療市場的主要企業：公司概況、產品系列、主要亮點、財務表現和策略。
- 透過利用本報告中提出的見解，企業行銷負責人和經營團隊可以就未來的產品發布、產品升級、市場擴張和行銷策略做出明智的決策。
- 本報告面向該產業的各類相關人員，包括投資者、供應商、產品製造商、經銷商、新參與企業和金融分析師。
- 透過分析先天性高胰島素血症治療全球市場所使用的各種策略矩陣，相關人員將能夠更輕鬆地做出決策。
目錄
第1章：研究目標與前提條件
- 研究目標
- 前提
- 簡稱
第2章 市場範圍
- 報告摘要
- 市場定義和範圍
- 執行摘要
- Coherent Opportunity Map（COM）
第3章：市場動態、監管與趨勢分析
- 市場動態
- 促進因素
- 阻礙因素
- 市場機遇
- 影響分析
- 市場趨勢
- 近期趨勢
- 收購與合作趨勢
- 法規環境
- 價格分析
- PEST分析
第4章 全球先天性高胰島素血症治療市場：依疾病類型分類，2026-2033年
- 概述
- KATP-HI
- GDH-HI
- GK-HI
- 其他（SCHAD HI、HNF4A/HNF1A HI 等）
第5章 全球先天性高胰島素血症治療市場：依藥物類型分類，2026-2033年
- 概述
- 二氮嗪
- Octreotide
- 升糖素
- 硝苯地平
- 其他藥物（Sirolimus、氯噻嗪等）
第6章 先天性高胰島素血症治療藥物的全球市場：依給藥途徑分類，2026-2033年
- 概述
- 口服
- 腸外
第7章 全球先天性高胰島素血症治療市場：依通路分類，2026-2033年
- 概述
- 醫院藥房
- 零售藥房
- 網路藥房
第8章 全球先天性高胰島素血症治療市場：按地區分類，2026-2033年
- 北美洲
- 美國
- 加拿大
- 拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 其他拉丁美洲
- 歐洲
- 英國
- 德國
- 義大利
- 法國
- 西班牙
- 俄羅斯
- 其他歐洲國家
- 亞太地區
- 中國
- 印度
- 日本
- ASEAN
- 澳洲
- 韓國
- 亞太其他地區
- 中東
- GCC
- 以色列
- 其他中東國家
- 非洲
- 北非
- 中非
- 南非
第9章 競爭情勢
- Zealand Pharma A/S
- Eli Lilly and Company
- Xeris Pharmaceuticals, Inc.
- Rezolute, Inc.
- Hanmi Pharm.Co., Ltd.
- Fresenius Kabi AG
- Eiger BioPharmaceuticals.
- Crinetics Pharmaceuticals, Inc.
- AmideBio,LLC
- Jolly Healthcare
- e5 Pharma, LLC.
- Merck &Co., Inc.
- Novo Nordisk A/S
- Amphastar Pharmaceuticals.Inc,
- USV Private Limited.
- Teva Pharmaceutical Industries Ltd.
第10章
- 調查方法
- 關於本公司
Congenital Hyperinsulinism Treatment Market is estimated to be valued at USD 158.4 Mn in 2026 and is expected to reach USD 321.6 Mn by 2033, growing at a compound annual growth rate (CAGR) of 8.2% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 158.4 Mn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 8.20% | 2033 Value Projection: | USD 321.6 Mn |
Congenital hyperinsulinism(CHI) also called as hyperinsulinemic hypoglycemia, a rare endocrine condition that causes low blood glucose levels and occurs mainly in newborn babies, infants and children leading to permanent brain injury and is most frequent cause of severe hypoglycemia. Over secretion of insulin by beta cells in pancreas leads to gene mutation in KATP channel genes (ABCC8 and KCNJ11, HNF4A, HNF1A, HADH, and UCP2 or activating mutations of GLUD1, GCK, and SLC16A1) that cause congenital hyperinsulinism. There is significant risk of permanent brain damage in CHI, hence it is necessary to make a prompt diagnosis and obtain immediate management of the disease to prevent complications such as epilepsy, cerebral palsy and neurodevelopmental deficits. According to the National Organization for Rare Disorders database, approximately 1/25,000 to 1/50,000 HI births occurs in most of the countries including HI develop hypoglycemia during the first month of life. Irritability, sleepiness, excessive hunger, rapid heart rate are common symptoms that occurs while more severe symptoms, such as seizures and coma occur. There are many causes of congential hyperinsulinism based on different forms of the disease for example there are transient forms while some are due to genetic defects and persist for life. Prematurely born babies sometimes, develop hypoglycemia due to excessive insulin secretion. The cause of this inappropriate insulin secretion is still not clear, but it can last a few days to months.
Market Dynamics
Ongoing research for development of novel therapeutic options for the treatment of congenital hyperinsulinismby various key players such as Zealand Pharma A/S, Hanmi Pharm.Co., Ltd., Eli Lilly and Company is anticipated to drive the growth of global congenital hyperinsulinismtreatment market over the forecast period. For instance, in May 2019, Zealand Pharma A/S, a biotechnology company initiated Phase 3 clinical trial of Dasiglucagon. The study aims to assess the efficacy and safety of Dasiglucagon for the treatment of pediatric patients with congenital hyperinsulinism. The study is estimated to be completed by December 2022. Dasiglucagon is a peptide analogue of glucagon consisting 7 amino acid substitutions engineered to eliminate fibril formation as well as peptide aggregation.
Key features of the study
- This report provides an in-depth analysis of the global congenital hyperinsulinism treatment market, and provides market size (US$ Million) and compound annual growth rate (CAGR%) for the forecast period (2022-2030), considering 2021 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global congenital hyperinsulinism treatment market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study are Zealand Pharma A/S, Eli Lilly and Company, Xeris Pharmaceuticals, Inc., Rezolute, Inc., Hanmi Pharm.Co., Ltd., Fresenius Kabi AG, Eiger BioPharmaceuticals., Crinetics Pharmaceuticals, Inc., AmideBio, LLC, Jolly Healthcare, e5 Pharma,LLC, Merck & Co.,Inc., Novo Nordisk A/S, Amphaster Pharmaceuticals,Inc., USV Private Limited, Teva Pharmaceutical Industries Ltd.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global congenital hyperinsulinism treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global congenital hyperinsulinism treatment market
Market Segmentation
- By Disease Type
- KATP-HI
- GDH-HI
- GK-HI
- Other (SCHAD HI,HNF4A/HNF1A, etc.)
- By Drug Type
- Diazoxide
- Octreotide
- Glucagon
- Nifedipine
- Other (Sirolimus, Chlorothiazide, etc.)
- By Route of Administration
- Oral
- Parenteral
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Regional Insights
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Key Players Insights
- Zealand Pharma A/S
- Eli Lilly and Company
- Xeris Pharmaceuticals, Inc.
- Rezolute, Inc.
- Hanmi Pharm.Co., Ltd.
- Fresenius Kabi AG
- Eiger BioPharmaceuticals.
- Crinetics Pharmaceuticals, Inc.
- AmideBio,LLC
- Jolly Healthcare
- e5 Pharma,LLC
- Merck & Co.,Inc.
- Novo Nordisk A/S
- Amphaster Pharmaceuticals,Inc.
- USV Private Limited
- Teva Pharmaceutical Industries Ltd.
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snapshot, By Disease Type
- Market Snapshot, By Drug Type
- Market Snapshot, By Route of Administration
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Market Trends
- Recent Developments
- Acquisitions and Partnerships Scenario
- Regulatory Scenario
- Pricing Analysis
- PEST Analysis
4. Global Congenital Hyperinsulinism Treatment Market, By Disease Type, 2026-2033, (USD Mn)
- Overview
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021-2033
- Segment Trends
- KATP-HI
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- GDH-HI
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- GK-HI
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Other (SCHAD HI, HNF4A/HNF1A HI, etc.)
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
5. Global Congenital Hyperinsulinism Treatment Market, By Drug Type, 2026 - 2033, (USD Mn)
- Overview
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021-2033
- Segment Trends
- Diazoxide
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Octreotide
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Glucagon
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Nifedipine
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Other (Sirolimus, Chlorothiazide, etc.)
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
6. Global Congenital Hyperinsulinism Treatment Market, By Route of Administration, 2026 - 2033, (USD Mn)
- Overview
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021-2033
- Segment Trends
- Oral
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Parenteral
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
7. Global Congenital Hyperinsulinism Treatment Market, By Distribution Channel, 2026 - 2033, (USD Mn)
- Overview
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021-2033
- Segment Trends
- Hospital Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Retail Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Online Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
8. Global Congenital Hyperinsulinism Treatment Market, By Region, 2026 - 2033, (USD Mn)
- Introduction
- Market Share Analysis, By Region, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, For Regions, 2021-2033
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Disease Type , 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026-2033, (USD Mn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Disease Type , 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026-2033, (USD Mn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Disease Type , 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026-2033, (USD Mn)
- UK
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Disease Type , 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026-2033, (USD Mn)
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Disease Type , 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026-2033, (USD Mn)
- GCC
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Disease Type , 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026-2033, (USD Mn)
- North Africa
- Central Africa
- South Africa
9. Competitive Landscape
- Zealand Pharma A/S
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Eli Lilly and Company
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Xeris Pharmaceuticals, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Rezolute, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Hanmi Pharm.Co., Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Fresenius Kabi AG
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Eiger BioPharmaceuticals.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Crinetics Pharmaceuticals, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- AmideBio,LLC
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Jolly Healthcare
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- e5 Pharma, LLC.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Merck & Co., Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Novo Nordisk A/S
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Amphastar Pharmaceuticals.Inc,
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- USV Private Limited.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Teva Pharmaceutical Industries Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
10. Section
- Research Methodology
- About Us
